Patents by Inventor Kurt R. Gehlsen

Kurt R. Gehlsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6462067
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: October 8, 2002
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020098224
    Abstract: An ophthalmic composition for use in reducing ocular irritation comprising histamine, at a concentration of between about 0.01 and 1.0% by weight, in a pharmaceutically acceptable carrier, adapted for ophthalmic administration.
    Type: Application
    Filed: November 30, 2001
    Publication date: July 25, 2002
    Inventor: Kurt R. Gehlsen
  • Publication number: 20020095001
    Abstract: The present invention relates to compositions and methods for treating cell damage caused by reactive oxygen species in relation to a variety of skin disorders. More specifically, the present invention relates to the treatment skin disorders through the topical delivery of reactive oxygen metabolite production or release inhibiting compounds.
    Type: Application
    Filed: February 6, 2002
    Publication date: July 18, 2002
    Inventor: Kurt R. Gehlsen
  • Publication number: 20020094323
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 9, 2001
    Publication date: July 18, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Patent number: 6407133
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various infectious disease states or pathologies. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: June 18, 2002
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6350785
    Abstract: The present invention relates to compositions and methods for treating cell damage caused by reactive oxygen species in relation to a variety of skin disorders. More specifically, the present invention relates to the treatment skin disorders through the topical delivery of reactive oxygen metabolite production or release inhibiting compounds.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: February 26, 2002
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventor: Kurt R. Gehlsen
  • Publication number: 20010023256
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Application
    Filed: April 12, 2001
    Publication date: September 20, 2001
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Publication number: 20010018059
    Abstract: The present invention relates to compositions and methods for treating cell damage caused by reactive oxygen species in relation to a variety of skin disorders. More specifically, the present invention relates to the treatment skin disorders through the topical delivery of reactive oxygen metabolite production or release inhibiting compounds.
    Type: Application
    Filed: January 19, 2001
    Publication date: August 30, 2001
    Inventor: Kurt R. Gehlsen
  • Patent number: 6270781
    Abstract: The present invention relates to compositions and methods for treating cell damage caused by reactive oxygen species in relation to a variety of skin disorders. More specifically, the present invention relates to the treatment skin disorders through the topical delivery of reactive oxygen metabolite production or release inhibiting compounds.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: August 7, 2001
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventor: Kurt R. Gehlsen
  • Patent number: 6242473
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: June 5, 2001
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6221893
    Abstract: Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: April 24, 2001
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6071942
    Abstract: Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity and for elevating histamine levels in individuals in need thereof. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: June 6, 2000
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 5547936
    Abstract: A method of inhibiting the invasion of cells, particularly malignant cells through an extracellular membrane by contacting the membrane-cell interface with synthetic Arg-Gly-Asp-containing peptides. In one embodiment, the invention provides peptides containing the amino acid sequence Arg-Gly-Asp-Thr, more specifically Gly-Arg-Gly-Asp-Thr-Pro, which inhibits the attachment of cells to type I collagen in addition to fibronectin and vitronectin, and a method of inhibiting the attachment of cells to type I collagen. The invention further provides an assay for quantitating the invasive quality of cells by determining the amount of such peptides necessary to prevent the cells from penetrating an extracellular membrane, such as an amniotic membrane, in vitro.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: August 20, 1996
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Erkki I. Ruoslahti, Michael D. Pierschbacher, Kurt R. Gehlsen
  • Patent number: 5180809
    Abstract: An adhesion receptor for laminin is provided. The receptor is isolated from cell or tissue extracts and fractionated on an affinity column composed of cell attachment-promoting fragments of laminin coupled to Sepharose.TM. in the presence of divalent cations. This receptor can be used to prepare specific antibodies for the analysis of the amount of laminin receptor expressed by cells and has other applications in cellular and tumor biology.
    Type: Grant
    Filed: May 25, 1989
    Date of Patent: January 19, 1993
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Erkki I. Ruoslahti, Eva Engvall, Kurt R. Gehlsen